Natera moved to expand its circulating tumor DNA capabilities by acquiring Foresight Diagnostics to integrate PhaseED‑seq phased‑variant technology and by collaborating with MEDSIR on the multicenter MiRaDoR trial. The acquisition aims to improve Signatera assay sensitivity and enable expansion into hematologic MRD testing. Separately, Natera will supply Signatera Genome testing for the MiRaDoR Phase II study in early HR+/HER2‑ breast cancer to guide therapeutic selection based on ctDNA dynamics. Natera emphasized that combining phased‑variant enrichment with serial ctDNA monitoring could refine MRD‑driven treatment decisions in solid and blood cancers.